دورية أكاديمية
أعرض في EDS

Gonadal steroids and body composition, strength, and sexual function in men.

التفاصيل البيبلوغرافية
العنوان: Gonadal steroids and body composition, strength, and sexual function in men.
المؤلفون: Finkelstein JS; Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. jfinkelstein@partners.org, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ
المصدر: The New England journal of medicine [N Engl J Med] 2013 Sep 12; Vol. 369 (11), pp. 1011-22.
نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Boston, Massachusetts Medical Society.
مواضيع طبية MeSH: Body Composition/*physiology , Estradiol/*deficiency , Libido/*physiology , Muscle Strength/*physiology , Testosterone/*deficiency, Adipose Tissue ; Adult ; Aromatase Inhibitors/administration & dosage ; Estradiol/blood ; Estradiol/physiology ; Goserelin/administration & dosage ; Humans ; Male ; Middle Aged ; Testosterone/blood ; Testosterone/physiology ; Young Adult
مستخلص: Background: Current approaches to diagnosing testosterone deficiency do not consider the physiological consequences of various testosterone levels or whether deficiencies of testosterone, estradiol, or both account for clinical manifestations.
Methods: We provided 198 healthy men 20 to 50 years of age with goserelin acetate (to suppress endogenous testosterone and estradiol) and randomly assigned them to receive a placebo gel or 1.25 g, 2.5 g, 5 g, or 10 g of testosterone gel daily for 16 weeks. Another 202 healthy men received goserelin acetate, placebo gel or testosterone gel, and anastrozole (to suppress the conversion of testosterone to estradiol). Changes in the percentage of body fat and in lean mass were the primary outcomes. Subcutaneous- and intraabdominal-fat areas, thigh-muscle area and strength, and sexual function were also assessed.
Results: The percentage of body fat increased in groups receiving placebo or 1.25 g or 2.5 g of testosterone daily without anastrozole (mean testosterone level, 44±13 ng per deciliter, 191±78 ng per deciliter, and 337±173 ng per deciliter, respectively). Lean mass and thigh-muscle area decreased in men receiving placebo and in those receiving 1.25 g of testosterone daily without anastrozole. Leg-press strength fell only with placebo administration. In general, sexual desire declined as the testosterone dose was reduced.
Conclusions: The amount of testosterone required to maintain lean mass, fat mass, strength, and sexual function varied widely in men. Androgen deficiency accounted for decreases in lean mass, muscle size, and strength; estrogen deficiency primarily accounted for increases in body fat; and both contributed to the decline in sexual function. Our findings support changes in the approach to evaluation and management of hypogonadism in men. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00114114.).
التعليقات: Comment in: N Engl J Med. 2013 Sep 12;369(11):1058-9. doi: 10.1056/NEJMe1305307. (PMID: 24024843)
Comment in: Nat Rev Urol. 2013 Nov;10(11):616. doi: 10.1038/nrurol.2013.223. (PMID: 24100518)
Comment in: Nat Rev Endocrinol. 2013 Dec;9(12):693-4. doi: 10.1038/nrendo.2013.211. (PMID: 24146027)
Comment in: N Engl J Med. 2013 Dec 19;369(25):2457. doi: 10.1056/NEJMc1313169. (PMID: 24350954)
Comment in: N Engl J Med. 2013 Dec 19;369(25):2455. doi: 10.1056/NEJMc1313169. (PMID: 24350955)
Comment in: N Engl J Med. 2013 Dec 19;369(25):2455-6. doi: 10.1056/NEJMc1313169. (PMID: 24350956)
Comment in: N Engl J Med. 2013 Dec 19;369(25):2456. doi: 10.1056/NEJMc1313169. (PMID: 24350957)
Comment in: N Engl J Med. 2013 Dec 19;369(25):2456. doi: 10.1056/NEJMc1313169. (PMID: 24350958)
Comment in: Asian J Androl. 2014 Mar-Apr;16(2):266-7. doi: 10.4103/1008-682X.122367. (PMID: 24385014)
Comment in: Eur Urol. 2014 Apr;65(4):843-4. doi: 10.1016/j.eururo.2013.12.029. (PMID: 24559900)
Comment in: J Urol. 2014 May;191(5):1351-3. doi: 10.1016/j.juro.2014.02.073. (PMID: 24745513)
Comment in: J Urol. 2017 Feb;197(2):284. doi: 10.1016/j.juro.2016.11.074. (PMID: 27998505)
References: Ageing Res Rev. 2009 Oct;8(4):339-48. (PMID: 19576300)
Clin Endocrinol (Oxf). 2007 Aug;67(2):218-24. (PMID: 17547681)
J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74. (PMID: 9661593)
J Clin Endocrinol Metab. 2001 Jun;86(6):2380-90. (PMID: 11397827)
Mol Cell Endocrinol. 2011 Aug 6;342(1-2):81-6. (PMID: 21664242)
J Clin Endocrinol Metab. 2005 Feb;90(2):678-88. (PMID: 15562020)
J Clin Endocrinol Metab. 1999 Aug;84(8):2647-53. (PMID: 10443654)
J Clin Endocrinol Metab. 2002 Feb;87(2):599-603. (PMID: 11836291)
FASEB J. 2009 Jan;23(1):232-40. (PMID: 18809737)
J Clin Endocrinol Metab. 2003 Jun;88(6):2673-81. (PMID: 12788872)
Calcif Tissue Int. 2001 Oct;69(4):189-92. (PMID: 11730247)
Am J Clin Nutr. 1999 Sep;70(3):405-11. (PMID: 10479203)
J Clin Endocrinol Metab. 1979 Jun;48(6):955-8. (PMID: 447801)
J Clin Endocrinol Metab. 2001 Feb;86(2):724-31. (PMID: 11158037)
Qual Life Res. 1995 Jun;4(3):207-20. (PMID: 7613531)
J Sports Med Phys Fitness. 1981 Dec;21(4):342-51. (PMID: 7339218)
J Appl Physiol (1985). 1997 Nov;83(5):1581-7. (PMID: 9375323)
J Clin Invest. 2000 Dec;106(12):1553-60. (PMID: 11120762)
J Clin Endocrinol Metab. 1983 Sep;57(3):557-62. (PMID: 6874890)
J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53. (PMID: 10946892)
Osteoporos Int. 2008 Oct;19(10):1465-71. (PMID: 18338096)
J Androl. 2001 Sep-Oct;22(5):718-31. (PMID: 11545281)
J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65. (PMID: 8954042)
J Clin Endocrinol Metab. 2002 Feb;87(2):589-98. (PMID: 11836290)
J Bone Miner Res. 2009 Oct;24(10):1728-35. (PMID: 19419308)
J Clin Endocrinol Metab. 2005 Mar;90(3):1502-10. (PMID: 15572415)
J Clin Endocrinol Metab. 2003 Jan;88(1):204-10. (PMID: 12519853)
J Gerontol A Biol Sci Med Sci. 2002 Feb;57(2):M76-99. (PMID: 11818427)
J Clin Endocrinol Metab. 1979 Dec;49(6):905-16. (PMID: 511978)
J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):3-9. (PMID: 11850201)
N Engl J Med. 2001 Sep 27;345(13):948-55. (PMID: 11575286)
Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81. (PMID: 11701431)
J Clin Endocrinol Metab. 1999 Jan;84(1):201-6. (PMID: 9920084)
Psychoneuroendocrinology. 2005 Jun;30(5):413-7. (PMID: 15721053)
J Clin Endocrinol Metab. 2001 Jun;86(6):2787-91. (PMID: 11397888)
J Clin Endocrinol Metab. 2001 Nov;86(11):5366-71. (PMID: 11701707)
J Urol. 2000 Feb;163(2):460-3. (PMID: 10647654)
J Clin Endocrinol Metab. 2004 Feb;89(2):718-26. (PMID: 14764787)
J Clin Invest. 1969 Dec;48(12):2191-201. (PMID: 5355335)
J Clin Endocrinol Metab. 2000 Sep;85(9):3276-82. (PMID: 10999822)
معلومات مُعتمدة: K24 DK002759 United States DK NIDDK NIH HHS; M01 RR001066 United States RR NCRR NIH HHS; R01 AG030545 United States AG NIA NIH HHS; K24 DK02759 United States DK NIDDK NIH HHS; RR-1066 United States RR NCRR NIH HHS
سلسلة جزيئية: ClinicalTrials.gov NCT00114114
المشرفين على المادة: 0 (Aromatase Inhibitors)
0F65R8P09N (Goserelin)
3XMK78S47O (Testosterone)
4TI98Z838E (Estradiol)
تواريخ الأحداث: Date Created: 20130913 Date Completed: 20130919 Latest Revision: 20240610
رمز التحديث: 20240610
مُعرف محوري في PubMed: PMC4142768
DOI: 10.1056/NEJMoa1206168
PMID: 24024838
قاعدة البيانات: MEDLINE
الوصف
تدمد:1533-4406
DOI:10.1056/NEJMoa1206168